- Home
- HEPS vs IMNM Comparison
HEPS vs IMNM Comparison
Compare HEPS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- IMNM
- Stock Information
- Founded
- HEPS 2000
- IMNM 2006
- Country
- HEPS Turkey
- IMNM United States
- Employees
- HEPS N/A
- IMNM 131
- Industry
- HEPS Catalog/Specialty Distribution
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- HEPS Consumer Discretionary
- IMNM Health Care
- Exchange
- HEPS Nasdaq
- IMNM Nasdaq
- Market Cap
- HEPS 811.7M
- IMNM 748.3M
- IPO Year
- HEPS 2021
- IMNM 2020
- Fundamental
- Price
- HEPS $2.66
- IMNM $8.76
- Analyst Decision
- HEPS
- IMNM Strong Buy
- Analyst Count
- HEPS 0
- IMNM 5
- Target Price
- HEPS N/A
- IMNM $26.40
- AVG Volume (30 Days)
- HEPS 348.8K
- IMNM 973.9K
- Earning Date
- HEPS 06-12-2025
- IMNM 05-12-2025
- Dividend Yield
- HEPS N/A
- IMNM N/A
- EPS Growth
- HEPS N/A
- IMNM N/A
- EPS
- HEPS N/A
- IMNM N/A
- Revenue
- HEPS $1,471,066,066.00
- IMNM $10,938,000.00
- Revenue This Year
- HEPS $22.80
- IMNM N/A
- Revenue Next Year
- HEPS $25.49
- IMNM $542.22
- P/E Ratio
- HEPS N/A
- IMNM N/A
- Revenue Growth
- HEPS 42.87
- IMNM N/A
- 52 Week Low
- HEPS $1.71
- IMNM $5.15
- 52 Week High
- HEPS $4.05
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- HEPS 45.42
- IMNM 58.34
- Support Level
- HEPS $2.56
- IMNM $7.83
- Resistance Level
- HEPS $2.90
- IMNM $9.04
- Average True Range (ATR)
- HEPS 0.11
- IMNM 0.53
- MACD
- HEPS 0.00
- IMNM 0.07
- Stochastic Oscillator
- HEPS 29.85
- IMNM 82.97
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.